Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Frequency of CD4+FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD

Bone Marrow Transplantation volume 48, pages 859–864 (2013)Cite this article

Subjects

Abstract

Acute GVHD (aGVHD) is a major obstacle to allogeneic hematopoietic SCT (alloHSCT). Although it is thought that aGVHD is initiated in secondary lymphoid organs at a very early stage of alloHSCT, whether CD4+FOXP3+ regulatory T-cells (Tregs) have an impact on aGVHD development during this period remains unclear. Here, we measured Tregs in peripheral blood as early as possible after HLA-mismatched alloHSCT, and assessed the incidence of aGVHD. Flow cytometric analyses revealed that at the second week after HSCT, patients with aGVHD had significantly (P=0.018) lower Treg:CD4+T-cell ratios than those without aGVHD. As these differences were seen before the development of aGVHD, these ratios can predict the incidence of aGVHD. The cumulative incidence of aGVHD in patients with ratios of <9% was significantly higher than that in patients with ratios of ⩾9% (P=0.0082, log-rank test). Additionally, the specific ratio of Tregs:CD4+T-cells was the most significant value among all other possible lymphocyte-associated ratios and absolute cell counts. These findings suggest that the ratio of Tregs:CD4+T-cells at the second week post HLA-mismatched alloHSCT might be a potent predictor of aGVHD in these patients. The practical efficacy of this finding should be verified in further interventional studies.

This is a preview of subscription content, access via your institution

Access options

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M . Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151–1164.

    CAS  Google Scholar 

  2. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA . CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245–1253.

    Article  CAS  Google Scholar 

  3. Taylor PA, Lees CJ, Blazar BR . The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493–3499.

    Article  CAS  Google Scholar 

  4. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S . Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389–399.

    Article  CAS  Google Scholar 

  5. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL . CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401–406.

    Article  CAS  Google Scholar 

  6. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903–2911.

    Article  CAS  Google Scholar 

  7. Meignin V, Peffault de Latour R, Zuber J, Regnault A, Mounier N, Lemaitre F et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol 2005; 33: 894–900.

    Article  CAS  Google Scholar 

  8. Sanchez J, Casano J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F et al. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004; 126: 697–703.

    Article  Google Scholar 

  9. Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061.

    Article  CAS  Google Scholar 

  10. Fontenot JD, Gavin MA, Rudensky AY . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330–336.

    Article  CAS  Google Scholar 

  11. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291–1297.

    Article  CAS  Google Scholar 

  12. Zhai Z, Sun Z, Li Q, Zhang A, Liu H, Xu J et al. Correlation of the CD4+CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD. Transpl Int 2007; 20: 440–446.

    Article  CAS  Google Scholar 

  13. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010; 16: 907–914.

    Article  Google Scholar 

  14. Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C, Desveaux A, Keyvanfar K et al. Th17/Treg ratio in human graft-versus-host disease. Blood 2010; 116: 1165–1171.

    Article  CAS  Google Scholar 

  15. Tamaki H, Ikegame K, Kawakami M, Fujioka T, Tsuboi A, Oji Y et al. Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia 2003; 17: 2052–2054.

    Article  CAS  Google Scholar 

  16. Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008; 36: 1–8.

    Article  CAS  Google Scholar 

  17. Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073–1084.

    Article  Google Scholar 

  18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  20. Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T . FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol 2007; 85: 154–162.

    Article  CAS  Google Scholar 

  21. Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.

    Article  CAS  Google Scholar 

  22. von Boehmer H . Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338–344.

    Article  CAS  Google Scholar 

  23. Duran-Struuck R, Reddy P . Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2008; 85: 303–308.

    Article  Google Scholar 

  24. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008; 112: 1539–1542.

    Article  CAS  Google Scholar 

  25. Willems E, Humblet-Baron S, Dengis O, Seidel L, Beguin Y, Baron F . Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplant 2010; 45: 1442–1448.

    Article  CAS  Google Scholar 

  26. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J . Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 2003; 9: 292–303.

    Article  CAS  Google Scholar 

  27. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998; 102: 1882–1891.

    Article  CAS  Google Scholar 

  28. Xun CQ, Tsuchida M, Thompson JS . Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 1997; 64: 297–302.

    Article  CAS  Google Scholar 

  29. Sakai R, Maruta A, Yanoma S, Shimizu A, Harada M, Nakamura Y et al. Effect of sublethal total body irradiation on acute graft-versus-host disease and graft-versus-leukemia effect in SCID mice. Bone Marrow Transplant 1997; 20: 183–189.

    Article  CAS  Google Scholar 

  30. Nestel FP, Price KS, Seemayer TA, Lapp WS . Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405–413.

    Article  CAS  Google Scholar 

  31. Schneider M, Munder M, Karakhanova S, Ho AD, Goerner M . The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Haematol 2006; 28: 382–390.

    Article  CAS  Google Scholar 

  32. Korngold R, Sprent J . Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol 1985; 135: 3004–3010.

    CAS  PubMed  Google Scholar 

  33. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005; 106: 1113–1122.

    Article  CAS  Google Scholar 

  34. Ewing P, Miklos S, Olkiewicz KM, Muller G, Andreesen R, Holler E et al. Donor CD4+T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. Exp Hematol 2007; 35: 155–163.

    Article  CAS  Google Scholar 

  35. Yu XZ, Albert MH, Anasetti C . Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells. J Immunol 2006; 176: 3383–3390.

    Article  CAS  Google Scholar 

  36. Amir AL, Hagedoorn RS, van Luxemburg-Heijs SA, Marijt EW, Kruisselbrink AB, Frederik Falkenburg JH et al. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA class I causing severe acute GVHD. Biol Blood MarrowTransplant 2012; 18: 210–219.

    Article  CAS  Google Scholar 

  37. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A et al. Regulatory T cells inhibit stable contacts between CD4+T cells and dendritic cells in vivo. J Exp Med 2006; 203: 505–511.

    Article  CAS  Google Scholar 

  38. Huang YH, Sojka DK, Fowell DJ . Cutting edge: regulatory T cells selectively attenuate, not terminate, T cell signaling by disrupting NF-kappaB nuclear accumulation in CD4 T cells. J Immunol 2012; 188: 947–951.

    Article  CAS  Google Scholar 

  39. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921–3928.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We appreciate the conscientious technical assistance of Ms Aya Yano and Ms Kimiko Yamamoto in the flow cytometric and donor−recipient chimerism analyses.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

    T Fujioka, H Tamaki, K Ikegame, S Yoshihara, K Taniguchi, K Kaida, R Kato, T Inoue, J Nakata, S Ishii, T Soma, M Okada & H Ogawa

Authors
  1. T Fujioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Tamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Ikegame
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Yoshihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Kaida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Soma
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Fujioka.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujioka, T., Tamaki, H., Ikegame, K. et al. Frequency of CD4+FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant 48, 859–864 (2013). https://doi.org/10.1038/bmt.2012.232

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.232

Keywords

This article is cited by

Search

Advanced search

Quick links